placebo + celecoxib

The intervention referred to as **placebo + celecoxib** represents the control arm of a specific randomized, double-blind clinical trial (NCT01838044) evaluating treatments for chronic low back pain with a neuropathic component. In this context, patients received active celecoxib (200 mg once daily) alongside a placebo designed to mimic pregabalin. Celecoxib is a small molecule nonsteroidal anti-inflammatory drug (NSAID) that acts as a selective cyclooxygenase-2 (COX-2) inhibitor. By specifically targeting the COX-2 enzyme, it reduces the synthesis of pro-inflammatory prostaglandins, thereby alleviating pain and inflammation. The trial was sponsored by Pfizer's Upjohn division, which subsequently merged with Mylan to form Viatris Inc. This arm served as a comparator to determine if the addition of pregabalin to standard celecoxib therapy provided superior pain relief compared to celecoxib alone.

Brand names

Celebrex

Other names

celecoxib monotherapycelecoxib plus placebo